Valery LEBOVKA, “FACTS”
The world health organization (who) has called “scientific breakthrough” the results of a British clinical study of RECOVERY, according to which the use of the corticosteroid dexamethasone helps to reduce the mortality rate among patients with disease caused by a novel coronavirus (COVID-19).
This is stated in a statement on Tuesday the statement of the official representative who Fadela shaib.
“This is the first treatment, [the results] demonstrate the reduction of mortality among patients with [caused by a novel coronavirus disease] COVID-19 — presented in the statement of the Director General of the organization of Tedros Adhanom of Gebreyesus. — That’s great news, and I congratulate the government of great Britain, University of Oxford, as well as numerous British hospitals and patients who have contributed to this is aimed at saving lives scientific breakthrough“.
According to guideline research Professor, University of Oxford Peter Horby, dexamethasone has become the “first drug to demonstrate an improvement in survival when COVID-19“.
Harbi believes that the drug should be immediately included in used in the world the protocols of treatment of coronavirus infection.
In the ongoing March of the study involved 11.5 thousand patients of the 175 British hospitals. The purpose of large-scale research project to study the effectiveness of the treatment methods are infected with coronavirus new. 2.1 thousand study participants received dexamethasone, however, also explored the efficacy of the antiretroviral drug lopinavir/ritonavir antibiotic azithromycin and the immunosuppressant tocilizumab, transfusion to patients blood plasma of patients undergoing COVID-19, and anti-malarial drug hydroxychloroquine. 4.3 thousand patients in the control group received only standard treatment.
Scientists failed to find evidence that hydroxychloroquine reduces mortality among patients COVID-19, to speed up the process of recovery or positive effect on the patients ‘ condition otherwise.
The use of dexamethasone in a dosage of 6 mg per day allowed to reduce by a third the mortality rate among patients on artificial lung ventilation (as compared with the control group), and one-fifth among the patients receiving oxygen. Among patients who did not require respiratory support, any effect have been identified.
Earlier, the “FACTS” wrote that the Minister of health of great Britain Matt Hancock made a statement in which he declared the drug ramdevpir the “biggest step forward” in the treatment of COVID-19. He said that the government has approved widespread use of this medication British physicians. In fact, ramdevpir was the first drug that received in Britain such status.